A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2141-2149

  Dijkgraaf, E M ^a   Santegoets, S J A M ^a   Reyners, A K L ^b   Goedemans, R ^a   Wouters, M C A ^b   Kenter, G G ^c   van Erkel, A R ^a   van Poelgeest, M I E ^a   Nijman, H W ^b   van der Hoeven, J J M ^a   Welters, M J P ^a   van der Burg, S H ^a   Kroep, Judith R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Belgium and Center Gynaecological Oncology Amsterdam (CGOA)   (Netherlands)

Author keywords

Chemoresistance; Immunotherapy; Interleukin 6; Ovarian cancer; Tumor immunity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PEGINTERFERON ALPHA2B; STAT3 PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COLON PERFORATION; CONSTIPATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; ILEUS; INFECTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUTROPHIL COUNT; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOEMBOLISM; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; CYSTADENOCARCINOMA, SEROUS; DOSE RESPONSE; ENDOMETRIAL NEOPLASMS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS;

EID: 84943791915     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv309     Document Type: Article

References (26)

1. Gooden M, Lampen M, Jordanova ES et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci USA 2011; 108: 10656-10661.
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
3. Reinartz S, Schumann T, Finkernagel F et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 2014; 134: 32-42.
4. Lavoue V, Thedrez A, Leveque J et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013;11: 147.
5. Charbonneau B, Goode EL, Kalli KR et al. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol 2013; 33: 137-164.
6. Coward J, Kulbe H, Chakravarty P et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-6096.
7. Plante M, Rubin SC, Wong GY et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73:1882-1888.
8. Zitvogel L, Apetoh L, Ghiringhelli F et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-738.
9. Dijkgraaf EM, Heusinkveld M, Tummers B et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013; 73: 2480-2492.
10. Preston CC, Maurer MJ, Oberg AL et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and F. PLoS One 2013;8: e80063.
11. Nishimoto N, Terao K, Mima T et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.
12. Shirota Y, Yarboro C, Fischer R et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 118-128.
13. Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus:data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542-552.
14. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
15. Zeestraten EC, Speetjens FM, Welters MJ et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013; 132: 1581-1591.
16. Bukowski R, Ernstoff MS, Gore ME et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002; 20:3841-3849.
17. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21:419-423.
18. Janetzki S, Britten CM, Kalos M et al. "MIATA"-minimal information about T cell assays. Immunity 2009; 31: 527-528.
19. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997.
20. Koskinas J, Zacharakis G, Sidiropoulos J et al. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy. J Med Virol 2009; 81: 848-852.
21. Roll P, Muhammad K, Schumann M et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011; 63: 1255-1264.
22. Carbone G, Wilson A, Diehl SA et al. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 2013; 9: 279-288.
23. Lee H, Pal SK, Reckamp K et al. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 2011; 344: 41-59.
24. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
25. Tugues S, Burkhard SH, Ohs I et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015; 22: 237-246.
26. Maccio A, Lai P, Santona MC et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998;69:248-252.